LRRC23 RABBIT PAB

: S221460

: LRRC23

LRPB7

UNIPROT ID: Q53EV4 (Gene Accession - NP_964013)

: The leucine-rich (LRR) repeat is a 20-30 amino acid motif that forms a hydrophobic ⏹/? horseshoe fold, allowing it to accommodate several leucine residues within a tightly packed core. All LRR repeats contain a variable segment and a highly conserved segment, the latter of which accounts for 11 or 12 residues of the entire LRR motif. The primary function of these motifs is to provide a versatile structural framework to mediate the formation of protein-protein interactions. LRRs are present in a variety of proteins with diverse structure and function, including innate immunity and nervous system development. Several human diseases are associated with mutations in genes encoding LRR-containing proteins. LRRC23 (leucine-rich repeat-containing protein 23), also known as leucine-rich protein B7, is a 343 amino acid protein that contains eight LRR (leucine-rich) repeasts and one LRRCT domain. LRRC23 exists as two alternatively spliced isoforms and is encoded by a gene mapping to chromosome 12.

: Synthetic peptide of human LRRC23

: ELISA, IHC

: IHC: 25-100; ELISA: 5000-10000

: Rabbit

Rabbit Polyclonal

: Immunogen-specific rabbit IgG

: Antigen affinity purification

: Human

: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

: Cell Biology

: Store at -20ºC. Avoid repeated freezing and thawing

Immunohistochemistry analysis of paraffin embedded Human thyroid cancer tissue using 221460(LRRC23 Antibody) at a dilution of 1/30(Cell membrane and Nucleus).

In comparision with the IHC on the left, the same paraffin-embedded Human thyroid cancer tissue is first treated with the synthetic peptide and then with 221460(Anti-LRRC23 Antibody) at dilution 1/30.

The image on the left is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using 221460(Anti-LRRC23 Antibody) at a dilution of 1/30.

In comparision with the IHC on the left, the same paraffin-embedded Human esophagus cancer tissue is first treated with synthetic peptide and then with D263061(Anti-LRRC23 Antibody) at dilution 1/30.